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Abstract
Background: The objective of the study was to explore the clinical expression, radiological and pathological
features, differential diagnosis, and biological behavior of a clear cell myomelanocytic tumor. In a case
involving a clear cell myomelanocytic tumor located in the hepatic falciform ligament, we evaluated clinical
expression, radiological characteristics, histopathology, immunohistochemistry, and biological behavior; we also
reviewed the relevant literature.
Case presentation: Clear cell myomelanocytic tumor is a benign soft-tissue neoplasm that often occurs in
women, and is expressed as a painless mass. The falciform ligament is its most frequent site of occurrence.
The imaging characteristics of this lesion were uneven enhancement in the arterial phase, continuing to
strengthen in the venous phase, and equal density in the balance phase. Histological and immunohistochemical
analysis revealed the main transparent epithelioid cells and smooth muscle spindle cells to be HMB-45(+), smooth
muscle actin(+), and melan-A (+).
Conclusion: Hepatic vascular epithelioid cell tumors are very rare mesenchymal neoplasms. Few studies have
investigated this tumor in the hepatic falciform ligament; consequently, its diagnosis and the selection of an
appropriate treatment and follow-up protocol are challenging. Treatment outcome remains unpredictable.
Therefore, clear cell myomelanocytic tumor should be viewed as a tumor with uncertain malignant potential
requiring long-term follow-up.
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Background
Perivascular epithelioid cell (PEComa) tumor has re-
cently been cytopathologically defined. Histological and
immunohistochemical analysis indicate that it has the
obvious characteristics of perivascular epithelioid cells
(PECs) [1, 2]. A type of tumor with hyaline cells that has
the characteristics and similarity to a neoplasm with
perivascular epithelioid cell differentiation is determined
as follows according to the World Health Organization
(2002) soft-tissue tumor classification: a neoplasm with
perivascular epithelioid cell differentiation, including
hepatic falciform ligament clear cell myomelanocytic tu-
mors [3]. Because soft-tissue clear cell myomelanocytic
tumor (CCMMT) is a newly identified tumor type, there
have been very few previous studies. This tumor usually
involves the uterus, followed by the sickle ligament and
gut. There have been only two reported cases of
CCMMT in the liver [4]; thus, the diagnosis and differ-
ential biological behavior of this neoplasm require fur-
ther study. The present report involves the evaluation of
a case of CCMMT and a review of the relevant
literature.
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Case presentation
A 29-year-old woman was admitted to our hospital in
July 2014 with liver cancer rupture after intervention
over a period of 1 month. She had a treatment history
involving L-carnitine drugs proceeded by cesarean sec-
tion (4 months ago), and no history of hepatitis and
hepatocirrhosis. A physical examination revealed the fol-
lowing: the right side of the abdomen was slightly
bloated; there was a 10-cm surgical scar on the hypogas-
trium, and a palpable 5 × 6 cm mass was present in the
right upper abdomen; the mass was hard, smooth, and
had good texture; and there was no pain when the mass
was pressed. Laboratory examination revealed routine
hepatic and renal function, and normal levels of serum
electrolytes and alpha fetoprotein.
Ultrasound examination of the digestive system
demonstrated the following: a heterogeneous hypere-
choic mass (15.5 × 9.6 × 14.2 cm) located in the right
hepatic lobe; an irregular anechoic area in the mass; a
clear boundary; and no obvious blood flow signal in
the mass examined using color Doppler flow imaging
(Fig. 1). A plain abdominal computed tomography
(CT) scan showed a huge abdominal mass below the
right segment of the anterior hepatic lobe, an uneven
internal density, and high and low mixed density
(Fig. 2). A dynamic enhanced CT scan of the upper
abdomen demonstrated the following: a mixed high-
and low-density mass shadow in the right anterior
hepatic lobe below segment S5; a clear boundary; a
neat outline; significant uneven enhancement; intern-
ally, a large area of low-density non-enhanced
shadow; multiple enlargement of the surrounding ves-
sels; and a low-density coated edge.
Hepatic arterial enhancement was uneven, but the ven-
ous and balance periods strengthened more evenly (Fig. 3).
A dynamic enhanced magnetic resonance imaging (MRI)
scan of the upper abdomen revealed the following: a huge
mass in the right anterior hepatic lobe; an uneven internal
density; an obvious uneven strengthening; and a visible li-
quefied necrotic area within the mass (Fig. 4). A hepatic
adenoma was diagnosed using the imaging data. During
surgery, the following was found: the mass was located in
the V segment of the liver; its diameter was approximately
10 cm; and the mass exhibited cystic and solid characteris-
tics, and had invaded the gallbladder and part of the hep-
atic segment VI. Consequently, the patient underwent
hepatic V segment excision, partial VI segment excision,
and gallbladder excision. Postoperative recovery was good.
Pathological examination
Macroscopic examination Macroscopic examination
revealed the following: a liver tissue of size 19 × 14 ×
7 cm; the presence of a nodular goiter in the liver after
sectioning with an area of 11 × 9 cm; the goiter was
grayish red and grayish yellow and had a crisp quality;
and there was partial invasion of the local liver capsule.
Microscopic examination Microscopic examination re-
vealed the following: the tumor had a high cell density;
cells were fusiform or ovoid in shape; in parts of the
tumor, the cells were epithelioid; the cytoplasm was
weakly acidophilic or bright; small nucleoli and nuclear
grooves were visible; mitotic figures were rare; there was
a diffuse distribution of tumor cells; the lesion had an
obscure boundary; a hemorrhage was present in part of
the tumor; necrosis was evident; and a multinucleated
giant cell reaction occurred. Liver cell edema associated
with mild cholestasis was observed in the surrounding
hepatic tissues, together with dilated vessels in the cen-
tral vein and portal area (Fig. 5).
Immunohistochemistry
Immunohistochemical analysis of tumor cells indicated
the following: HMB-45(+); vimentin(+); smooth muscle
actin (SMA)(+); melan-A(+); CK(−); hepatocyte(−); Arg-
1(−); GPC-3(−); CK7(−); CK19(−); CK20(−); S-100(−);
CD34 blood vessel endothelium(+); and no exact tumor
suppository (Figs. 6 and 7). The pathological diagnosis
was a hepatic falciform ligament clear cell myomelano-
cytic tumor.
Fig. 1 Ultrasound scan of the digestive system. A heterogeneous high echogenic mass can be seen in the right liver lobe. An irregular anechoic
area is also evident in the mass; color Doppler flow imaging showed no obvious blood signal in it
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Discussion
PEComa is a tumor family that includes the following:
angiomyolipoma (AML), a clear cell “sugar” tumor of
the lung (CCST); lymphangioleio-myomatosis (LAM),
CCMMT with rare occurrence in the pancreas; and lu-
cency cell tumors in the rectum, peritoneum, uterus,
and other organs. The other tumors occur in many parts
of the body, including the chest, gastrointestinal tract,
sinus, bone trunk, and liver; most have been described
exclusively in case reports [5–8]. In 1992, Bonetti et al.
[9] first proposed the name lung hyaline cell “sugar”
tumor for angioleiomyolipoma and lymphangioleiomyo-
matosis cells with the same morphology and immune
phenotype as PECs. In 1996, Zamboni et al. [10] re-
ported a case of lung hyaline cell “sugar” tumor, which
was very similar to pancreas hyaline cell tumor; conse-
quently, we suggested the term PEComa for PEC tumors
located in different places and with no connection.
Armah et al. [11] proposed that PEComa tumors, with
the exception of AML, LAM, and CCST, should be
named PEComa-NOS (not otherwise specified) tumors,
or should be known by some other name such as
CCMMT or primary extrapulmonary sugar tumor; they
used monotype epithelioid AML as a synonym of
PEComa. The name PEC sarcoma has been changed to
PEComa. CCMMT is one of the tumors originating
from blood vessels surrounding epithelioid cells. In our
case, the CCMMT in the falciform ligament belonged to
the PEComa family.
Clinical characteristics
Jafari et al. [12] reported the following: hepatic PEComa
occurred more often in women; the peak incidence was
in patients aged 40–70 years; it occurred more fre-
quently in the liver; many of the tumors were solitaryand
easily misdiagnosed as hepatocellular carcinoma; and a
few tumors exhibited malignant behavior. The onset of
the disease manifests insidiously, and most patients have
no history of liver diseases. The symptoms and signs of
the disease reveal no specificity; furthermore, they are
similar to other tumors arising from the liver. Generally,
indigestion, loss of appetite, nausea, and intermittent
colic pain can occur. On physical examination, tender-
ness to palpation and liver enlargement may be ob-
served; in some patients, these tumors have been
detected by means of imaging examination during a
health check-up. The tumor markers AFP, CEA, and
CA19-9 were all negative. Most patients were diagnosed
after a postoperative pathological examination [13, 14].
Priola et al. [15] reported a case of acute abdominal dis-
ease caused by PEComa.
Fig. 2 Upper abdominal computed tomography scan. A giant tumor can be seen in the right anterior superior segment of the liver. Its internal
density is uneven and exhibits a high/low/equal mix
Fig. 3 Upper abdominal dynamic enhancement computed tomography scan. Hepatic arterial enhancement is uneven, but the strengthening of
the venous and balance periods is more even
Wang et al. BMC Cancer  (2015) 15:1004 Page 3 of 9
Imaging manifestations
Imaging manifestations of hepatic PEComa have rarely
been mentioned in previous studies. Hepatic PEComa
exhibits a variety of imaging findings. Ameurtesse et al.
[16] found that hepatic PEComa could be expressed as a
range of echo types under ultrasound examination, and,
in most of the conditions, the lesions or tissue surround-
ing the lesions expressed a rich blood supply. Generally
in the CT or MRI scans, the lesions in the arterial phase
strengthen more obviously, continue to strengthen in
the venous phase; delayed scanning usually reveals equi-
density [17–19].
Most of the lesions show low signal intensity in T1-
weighted imaging, and high signal intensity in T2-
weighted imaging; a rich tumor blood supply is usually
associated with liver cancer and liver hemangioma [20].
Preoperative imaging studies (CT and MRI) have poor
diagnostic sensitivity regarding PEComa; the reported
preoperative diagnostic accuracy of CT and MRI is
15.7 % (11/70) and 22.7 % (10/44), respectively [21]. Im-
aging findings regarding our case were basically the
same as those previously reported. The lesion had a
liquefied necrotic area, strengthening of the liver paren-
chyma in the arterial phase was uneven, and strengthen-
ing in the intravenous and balance periods were even.
The preoperative diagnosis was hepatic adenoma, and
postoperative pathology revealed CCMMT located in
the hepatic falciform ligament. There have been numer-
ous reports regarding AML imaging, but reports con-
cerning the imaging features of CCST, LAM, and
CCMMTs are rare; preoperative imaging diagnosis is dif-
ficult and mainly relies on postoperative pathologic
examination.
Pathological features and immunohistochemistry
Pathological characteristics
PEComa tumor cells always surround blood vessels and
are arranged in a radiated or sleeve pattern. Usually, the
adjacent blood vessel cells are epithelioid in shape; cells
that are located far from the blood vessels have a fusi-
form shape and the appearance of smooth muscle cells.
The cytoplasm of the tumor cells is clear and eosino-
philic [22], the nucleus is usually small and round or
oval in shape, has a small nucleolus, contains fine chro-
matin, is located in the meso-position, and nuclear div-
ision is rarely seen. However, in a few cases it is possible
to observe obvious hyperchromatic irregular-shaped nu-
clei, an increase in the size of the nucleolus, an increase
in the number of mitotic figures, the presence of mela-
nophores, focal necrosis, and an intravascular tumor
embolus; these findings indicate a poor prognosis [23–
25]. PEComa-NOS and PEComa occurring in different
regions of the body are similar. The lesion can be
formed by epithelioid PECs and is referred to as CCST
like; it can also be formed by fusiform PECs, and usually
appears similar to the funicular line that is referred to as
CCMMT like.
Immunohistochemistry
PEComa tumors have similar immunohistochemical
characteristics, mainly including melanin cell markers
(HMB-45 and/or melan A) and smooth muscle cell
Fig. 4 Magnetic resonance imaging scan of the upper abdomen. The mass exhibits uneven strengthening and the internal liquefied necrotic
area has no strength
Fig. 5 Microscopic examination. Tissue sections after hematoxylin-
eosin staining were observed at 400× magnification
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markers (microfilament protein and/or desmin) [22].
In 1991, two studies reported that hepatic and kidney
PEComa tumors were all positive for HMB-45 [26,
27]. These findings were confirmed in the present
study. Melanocytes and smooth muscle cell markers
play a significant role in the diagnosis of this type of
tumor [28, 29]. In previous studies, it was believed
that PEComa tumors simultaneously expressed mel-
anocyte and smooth muscle cell markers. However, a
study by Folpe et al. demonstrated that only 80 % of
cases simultaneously expressed these two types of
markers [6]. Thus, negativity for smooth muscle cell
markers did not rule out the diagnosis of having this
disease [30]. Ameurtesse et al. [16] concluded that
the immunohistochemical characteristics of hepatic
PEComas included: generally positive expression of
HMB-45; frequently positive expression of melan-A
and SMA; and negative expression of S100, desmin,
and vimentine. With the exception of the immunohis-
tochemical markers detailed above, the expression of
other markers including CD34 and CD117 differed
between PEComas [18, 31, 32].
Differential diagnosis
The differential diagnosis of CCMMT relies predom-
inantly on cell morphology and immunohistochemis-
try [33].
Soft-tissue clear cell sarcoma
Both soft-tissue clear cell sarcoma and CCMMT occur
more frequently in dense connective tissue, have
Fig. 6 Immunohistochemistry 1. Immunohistochemical analysis of tumor cells indicated the following: HMB-45(+), vimentin(+), smooth muscle
actin (SMA)(+), melan-A(+,CK(−), and hepatocyte(−)
Fig. 7 Immunohistochemistry 2. Immunohistochemical analysis of tumor cells indicated the following: Arg-1(−), GPC-3(−), CK7(−), CK19(−), CK20(−),
and S-100 (−)
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common clear cells and nucleoli, visible melanin parti-
cles, and the tumor cells express HMB-45; thus, they are
easily confused. However, soft-tissue clear cell sarcoma
always occurs in limb tendons and the tendon mem-
brane area. It has the following characteristics: the cells
are fusiform; it typically has a nest-like distribution; the
nucleolus is bigger and more obvious than those in
CCMMT cells; it shows strong basophilia; and it has a
lack of characteristic vascular components [34]. Immu-
nohistochemistry may be valuable in distinguishing be-
tween these two tumor types. CCMMT co-expresses
melanocytic markers and smooth muscle markers but
lack S-100 protein expression, whereas clear cell
sarcoma in the tendons and aponeuroses express both
S-100 protein and the melanocytic markers, but do not
express smooth muscle actin or myosin [35, 36].
Malignant clear cell mesothelioma
All malignant clear cell mesotheliomas occur in the ab-
dominal cavity and have clear cells. However, malignant
clear cell mesothelioma exhibits the following character-
istics: malignant progression, always with ascites; a
tendency to grow in the peritoneum; a nodular-like ap-
pearance; the presence of clear cells that are partially
gland like; the edematous degeneration of papilloma epi-
thelial cells; lipid accumulation in foam sample cells can
occur; and immunohistochemically it is positive for CK
and Vim. Its positivity for the mesothelial cell-related
antibody allows it to be distinguished from CCMMT
cells [33, 37].
Clear cell leiomyoma
Clear cell leiomyoma cells are similar to CCMMT clear
cells and smooth muscle spindle cells, and have compar-
able positive expression of SMA; however, CCMMT cells
have a lighter nucleus, its entire cytoplasm appears clear,
vacuoles in some cells compress the nucleus and show a
signet ring shape, and the epithelioid cells all exhibit a
funicular distribution. Clear cell leiomyoma cells do not
express HMB-45, and can therefore also be distinguished
from CCMMT cells [38].
Dedifferentiated liposarcoma
The key factor in the diagnosis of dedifferentiated lipo-
sarcoma is to determine if the tumor contains true lipo-
blasts; liposarcoma can also express S100 protein, but
not HMB-45 [39].
Leiomyosarcoma
Leiomyosarcoma differs from CCMMT in that it dis-
plays shorter fascicles that intersect at right angles to
one another, more pronounced cytoplasmic eosinophi-
lia,and elongated nuclei with blunt ends [33]. The nested
growth pattern, the vesicular nuclei with small
prominent nucleoli, and the rather uniform clear cell
change that characterize CCMMT would not usually be
expected to be encountered in leiomyosarcoma. In
addition, leiomyosarcoma usually does not express anti-
bodies to melanosomal proteins, such as S-100 or
melan-A [40, 41]. Additionally, the majority of leiomyo-
sarcomas express desmin [42], in contrast to CCMMTs,
which are desmin negative.
Monotypic angiomyolipoma
Recently, monotypic angiomyolipomas which differ from
the usual angiomyolipoma have been described. They con-
sist entirely or nearly entirely of perivascular epithelioid
cells with only rare thick-walled blood vessels or areas of
“adipocytic differentiation”. These tumors differ signifi-
cantly from CCMMTs because they are composed of epi-
thelioid cells and exhibit a lack of the spindled cells with
cytoplasmic clearing and the characteristic nested growth
pattern of CCMMT [43, 44]. CCMMT should also not be
confused with malignant angiomyolipoma. These tumors
differ from CCMMTs in that they show sarcomatous dif-
ferentiation with marked nuclear pleomorphism, elevated
mitotic activity, and necrosis [1, 46].
Other common differential diagnoses include: epitheli-
oid sarcoma; hepatic adenoma and carcinoma; gastro-
intestinal stromal tumors; metastatic sarcomatoid renal
cell carcinoma; paraganglioma; and oncocytic and clear
cell carcinoma. The positivity for melanocytic markers
and the negativity for multiple markers including CK,
CD34, S-100, and EMA confirm the diagnosis (Table 1)
[22, 14, 16].
Biological behavior
Blood vessels surrounding the epithelioid cells in the
tumor are characteristic of benign and malignant un-
defined tumors. Most patients with PEComas demon-
strate benign biological behavior and unfavorable
prognosis, while a few have malignant behavior and an
unfavorable prognosis [6, 46]. At present, there are no
clear diagnostic criteria for malignant PEComa; the
clinical biological behavior of the tumor has always been
controversial. According to the World Health
Organization 2003 guidelines, a PEComa tumor should
be viewed as malignant if it exhibits the following fea-
tures: infiltrating growth; a high cell density, nuclear en-
largement and hyperchromatism; an increased number
of mitotic figures; and atypical nuclear division and co-
agulative necrosis are present. In 2005, Flope et al. [6]
studied 26 cases of PEComa that occurred in the soft tis-
sue and gynecologic reproductive organs; they proposed
a series of standards whereby it could be subdivided into
tumors having benign characteristics, uncertain malig-
nant potential, or malignant potential.
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Diagnostic criteria for malignant PEComa should in-
clude two or more of the following: tumor size >5 cm;
infiltrative growth; a high nuclear and cell density; a mi-
totic ratio ≥1/50 high power; and signs of coagulative
necrosis and vascular invasion. PEComa of uncertain
malignant potential only exhibits polymorphism/multi-
core giant cells, or only has a size >5 cm, but no other
histological abnormalities. Benign PEComa tumors are
<5 cm in size and have no other histologic abnormal-
ities. These criteria have gradually been applied in
PEComa diagnosis, but still have limitations, and there
are special cases were they are not applicable; for ex-
ample, in long-term lymphangioleiomyomatosis involv-
ing a wide range, the influence of pulmonary interstitial
fibrosis caused by the disease is similar to the effects of
a tumor. The recurrence and metastasis of epithelioid
PEComa is apparently higher than is the case in normal
PEComa. Thus, an accurate assessment of the biological
behavior of PEComa and prognosis data accumulated
from more cases and clinical long-term follow-up stud-
ies will be required.
Treatment and prognosis
Currently, excision is the only method that has been
used to treat this disease, and can achieve a radical
cure in most cases. Although most PEComa tumors
exhibit benign behavior, there have been reports of
local invasion and remote metastasis [47, 48]. In
addition, there have been a few reports of remote me-
tastasis in post-excision cases [48–50]. However, no
other effective method is currently available for the
treatment of malignant PEComa, especially post-
operation. In a study by Martignoni et al. [1], it was
shown that activated mTORC1 to TSC, related or not
related to PEComa, had an important function; an
mTORC1 inhibitor such as rapamycin may have a
therapeutic effect regarding PEComa. In an animal
TSC model study that preceded the preclinical phase
study, a significant curative effect was demonstrated;
the same treatment protocol was also effective in kid-
ney AML. Wagner et al. [51] evaluated oral adminis-
tration of the mTOR inhibitor sirolimus in the
treatment of three cases of malignant PEComa; the
imaging data revealed that the tumor responded to
treatment, indicating that it could potentially be used
as a targeted therapy for PEComa. Italiano et al. [52]
reported cases where the mTOR inhibitor temsiroli-
mus had the same effect; however, more clinical trials
are required to confirm this finding. Long-term close
follow-up of patients with PEComa is necessary, and
PET-CT can be used as part of the follow-up examin-
ation protocol [53, 54].
Conclusions
An epithelioid cell tumor surrounded by hepatic blood
vessels is a very rare gastrointestinal mesenchymal
tumor; a hepatic falciform ligament CCMMT belongs to
this group. Relevant studies regarding the methods used
for its diagnosis are rare.
Treatment methods and questions concerning the de-
sign of the follow-up protocol remain a challenge, and
prognosis continues to be unpredictable. All of these le-
sions should be diagnosed as tumors with uncertain ma-
lignant potential, which require stricter long-term
follow-up evaluation.
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Table 1 Immunohistochemistry in the differential diagnosis of CCMMT




S-100 negative positive variable positive
CK negative positive negative negative
EMA negative positive negative
CD34 positive positive
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